Skip to main content
Premium Trial:

Request an Annual Quote

Protein Sequencing Firm Quantum-Si to Go Public Through Special Purpose Acquisition Company Merger

NEW YORK – Proteomics firm Quantum-Si plans to list on the Nasdaq through a merger with special purpose acquisition company HighCape Capital Acquisition Corp.

Guilford, Connecticut-based Quantum-Si has entered a definitive business combination agreement with HighCape and is expected to receive $425 million via a private investment in public equity (PIPE) transaction from investors including Foresite Capital Management, Eldridge, accounts advised by ARK Invest, Glenview Capital Management, and Redmile Group.

The pro forma equity value of the business combination is $1.46 billion, with the combined company expected to have an estimated $514 million in cash after closing, which includes up to $115 million in cash held in HighCape's trust account. Quantum-Si Founder and Executive Chairman Jonathan Rothberg will become executive chairman of the combined company.

The transaction is expected to close in Q2 2021, after which the company's stock will trade on the Nasdaq under the symbol QSI.

Quantum-Si's technology uses a sequencing approach it calls Quantum Si Time Domain Sequencing combined with a semiconductor sensing device to sequence proteins, including post-translational modifications, at the single-molecule level. The company plans to launch its first platforms in 2022 for research use.

"Quantum-Si's business strategy aligns well with our investment philosophy," said Kevin Rakin, CEO of HighCape Capital. "We have confidence that this highly passionate and experienced management team is well-positioned to deliver on its bold vision of revolutionizing the proteomics market. We look forward to supporting Quantum-Si and building a sustainable business that will be a disruptive force in the proteomics industry in the years to come."

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.